The Molecular Glue Landscape

Monovalent degraders and molecular glues have received increasing amounts of attention and investment over the past few years, with an increasing number of them entering the clinic (three in 2021 and three more in 2022). With more companies entering the space there is a drive for collaboration in order to facilitate the development of assets from discovery to commercialisation.

With the current focus on their activity and potential (and in partnership with the Molecular Glue Drug Development Summit) our Beacon TPD team have created an infographic of the landscape so far.

Molecular Glue Landscape Infographic

About the Infographic

The data in this infographic has been analyzed and carefully selected by the Beacon TPD Research Team and the producers of the Molecular Glue Drug Discovery Summit (January 24 – 26, 2023), using preclinical and clinical data from the Beacon TPD database, to provide you with the latest insights into the molecular glue landscape.

The infographic reviews the landscape by therapeutic class, phase of development, ligases and top developers.

You May Also Be Interested In…

What is Beacon?

Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.

Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.

This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.

We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!

Request Demonstration

Menu
Search Icon
Close Icon
Search